Publication | Closed Access

Serum fibroblast growth factor 21 is predictive of combined cardiovascular morbidity and mortality in patients with type 2 diabetes at a relatively short-term follow-up

Metabolic SyndromeFibrosisShort-term Follow-upCardiovascular DiseaseDiabetesType 2PathologyFibroblast Growth FactorDiabetes MellitusCombined Cardiovascular MorbidityPublic HealthMicrovascular DysfunctionMedicineAtherosclerosisEpidemiology